Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

Mark D Willis; Trevor P Pickersgill; Neil P Robertson; Richard W J Lee; Andrew D Dick; Ester Carreño

doi:10.1007/s10792-016-0370-9

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

Mark D Willis, Trevor P Pickersgill, Neil P Robertson, Richard W J Lee, Andrew D Dick, Ester Carreño

Research output: Contribution to journal › Article (Academic Journal) › peer-review

13 Citations (Scopus)

230 Downloads (Pure)

Abstract

PURPOSE: The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.

METHODS: Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.

RESULTS: A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.

CONCLUSIONS: To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.

Original language	English
Pages (from-to)	1229-1233
Number of pages	5
Journal	International Ophthalmology
Volume	37
Issue number	5
Early online date	11 Oct 2016
DOIs	https://doi.org/10.1007/s10792-016-0370-9
Publication status	Published - Oct 2017

Keywords

Multiple sclerosis
Uveitis
Alemtuzumab
Intraocular inflammation

Access to Document

10.1007/s10792-016-0370-9

Full-text PDF (accepted author manuscript)
This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Springer Verlag at DOI: 10.1007/s10792-016-0370-9. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 322 KB
Supplementary information Figure 1
This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Springer Verlag at DOI: 10.1007/s10792-016-0370-9. Please refer to any applicable terms of use of the publisher.
Other version, 3.72 MB
Supplementary information Figure 2
This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Springer Verlag at DOI: 10.1007/s10792-016-0370-9. Please refer to any applicable terms of use of the publisher.
Other version, 3.25 MB

Handle.net

Persistent link

Cite this

@article{1a6419dec2b748eba5431cdc4bae3fde,

title = "Alemtuzumab-induced remission of multiple sclerosis-associated uveitis",

abstract = "PURPOSE: The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.METHODS: Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.RESULTS: A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.CONCLUSIONS: To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.",

keywords = "Multiple sclerosis, Uveitis, Alemtuzumab, Intraocular inflammation",

author = "Willis, {Mark D} and Pickersgill, {Trevor P} and Robertson, {Neil P} and Lee, {Richard W J} and Dick, {Andrew D} and Ester Carre{\~n}o",

year = "2017",

month = oct,

doi = "10.1007/s10792-016-0370-9",

language = "English",

volume = "37",

pages = "1229--1233",

journal = "International Ophthalmology",

issn = "0165-5701",

publisher = "Springer Verlag",

number = "5",

}

TY - JOUR

T1 - Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

AU - Willis, Mark D

AU - Pickersgill, Trevor P

AU - Robertson, Neil P

AU - Lee, Richard W J

AU - Dick, Andrew D

AU - Carreño, Ester

PY - 2017/10

Y1 - 2017/10

N2 - PURPOSE: The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.METHODS: Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.RESULTS: A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.CONCLUSIONS: To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.

AB - PURPOSE: The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.METHODS: Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.RESULTS: A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.CONCLUSIONS: To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.

KW - Multiple sclerosis

KW - Uveitis

KW - Alemtuzumab

KW - Intraocular inflammation

U2 - 10.1007/s10792-016-0370-9

DO - 10.1007/s10792-016-0370-9

M3 - Article (Academic Journal)

C2 - 27730316

SN - 0165-5701

VL - 37

SP - 1229

EP - 1233

JO - International Ophthalmology

JF - International Ophthalmology

IS - 5

ER -

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this